Lantheus Holdings Intrinsic Value Calculator – LANTHEUS HOLDINGS Reports Fourth Quarter FY2022 Earnings on February 23, 2023

Earnings report

Lantheus Holdings Intrinsic Value Calculator – On February 23, 2023, LANTHEUS HOLDINGS ($NASDAQ:LNTH) reported their fourth-quarter FY2022 earnings. According to the financial statement released on December 31, 2022, the company’s total revenue for this period amounted to USD -119.2 million, which is a decrease of 196.3% compared to the same quarter in the previous year. Despite the decline in revenue, the reported net income of USD 263.2 million marks an increase of 103.1% from the same quarter in the prior year. The company attributed their decline in revenue to the impacts of the ongoing global pandemic on the economy and market conditions.

The reported net income for the fourth quarter of FY2022 signals a positive outlook for LANTHEUS HOLDINGS going forward. With sound management and smart strategies, the company has demonstrated it is capable of weathering difficult times and coming out stronger than ever before. The earnings report serves as evidence of LANTHEUS HOLDINGS’ resilience, and their expected growth in coming quarters is reason for optimism.

Share Price

LANTHEUS HOLDINGS reported its earnings for the fourth quarter of fiscal year 2022 on Thursday, February 23, 2023. The stock opened at $70.0 and closed at the same price, experiencing a surge of 20.2% from its previous closing price of 58.2. The share price demonstrated an impressive jump, indicating that the company is in a strong position and confident about its future prospects. Investors have reacted positively to this news, suggesting that they believe in the company’s ability to generate profits and deliver value to shareholders. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Lantheus Holdings. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Lantheus Holdings. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Lantheus Holdings. More…

Key Ratios Snapshot

Some of the financial key ratios for Lantheus Holdings are shown below. More…

Analysis – Lantheus Holdings Intrinsic Value Calculator

At GoodWhale, we recently did an analysis of LANTHEUS HOLDINGS‘s fundamentals and our proprietary Valuation Line pointed to a fair value of $57.0 for the company’s share. Currently, the stock is trading at around $70.0, meaning it is overvalued by 22.8%. This provides investors with a great opportunity to get into the stock at a discounted price. More…

Peers

The company operates through two segments, Diagnostic Imaging and Therapeutic Imaging. The Diagnostic Imaging segment provides contrast media products and related services used in diagnostic imaging procedures. The Therapeutic Imaging segment provides nuclear imaging products and services used in molecular and nuclear medicine procedures. Lantheus Holdings Inc’s competitors include RadNet Inc, Akumin Inc, and Todos Medical Ltd. RadNet Inc is a provider of outpatient diagnostic imaging services in the United States. Akumin Inc is a provider of diagnostic imaging services in the United States and Canada. Todos Medical Ltd is a biotechnology company that develops and commercializes blood tests for the early detection of cancer.

– RadNet Inc ($NASDAQ:RDNT)

RadNet, Inc. is a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2020, RadNet operated a network of 284 outpatient imaging centers located in California, Delaware, Maryland, Massachusetts, New Jersey, New York and Virginia. RadNet’s core business is providing high-quality diagnostic imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital x-ray, diagnostic radiology and fluoroscopy, at its outpatient imaging centers.

– Akumin Inc ($NASDAQ:AKU)

Akumin Inc is a holding company that, through its subsidiaries, provides outpatient diagnostic imaging services in the United States. It operates through the following segments: Imaging Centers and Mobile Imaging. The Imaging Centers segment consists of fixed-site imaging centers that provide magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, general x-ray, and diagnostic cardiology services. The Mobile Imaging segment acquires, leases, and operates mobile imaging equipment that provides magnetic resonance imaging, computed tomography, ultrasound, and general x-ray services. The company was founded on December 12, 2005 and is headquartered in Dallas, TX.

– Todos Medical Ltd ($OTCPK:TOMDF)

Todos Medical Ltd has a market cap of 19.09M as of 2022, a Return on Equity of 43.06%. The company is engaged in the business of providing diagnostic products and services for the early detection, diagnosis and prognosis of cancer and other diseases. The company’s products and services include blood tests, tissue tests and imaging services. The company’s blood tests are used to detect the presence of cancer cells in the blood, while its tissue tests are used to detect the presence of cancer cells in the tissue. The company’s imaging services are used to detect the presence of cancer cells in the body.

Summary

Lantheus Holdings reported a total of USD 119.2 million in revenue in the quarter, dropping significantly compared to the same period of the previous year. However, the company made a net income of USD 263.2 million, which marked an increase of 103.1% year-over-year. After the release of the quarter results, the stock price increased, showcasing investor confidence in the company’s strong performance. Overall, the quarter was successful for Lantheus Holdings, and it is likely to remain a safe and worthwhile investment for investors in the future.